Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2018-06-13, Stock:ABBV, The news for the past five days is as follows:
2018-06-06: NEWS1: Gilead Collaborates with Hookipa for HBV and HIV Therapies.NEWS2: Gilead Collaborates with Hookipa for HBV and HIV Therapies.NEWS3: Abbvie's (ABBV) Upadacitinib Fifth RA Study Data Positive.NEWS4: Abbvie's (ABBV) Upadacitinib Fifth RA Study Data Positive.NEWS5: ASCO Ends: Winners & Losers at the Key Cancer Research Event.NEWS6: ASCO Ends: Winners & Losers at the Key Cancer Research Event.NEWS7: Abbvie&apos;s (ABBV) Upadacitinib Fifth RA Study Data Positive.NEWS8: ASCO Ends: Winners & Losers at the Key Cancer Research Event.NEWS9: 2 Cheap Dividend Stocks You Can Buy Right Now.NEWS10: 2 Cheap Dividend Stocks You Can Buy Right Now.NEWS11: 2 Cheap Dividend Stocks You Can Buy Right Now.
2018-06-07: NEWS1: Should You Stick With Gilead Sciences?.NEWS2: Should You Stick With Gilead Sciences?.NEWS3: [$$] Big Pharma's Tempting Payouts.
2018-06-08: NEWS1: AbbVie Announces U.S. FDA Approval of VENCLEXTA® (venetoclax tablets) in Combination with Rituximab as a Fixed Duration Treatment for Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Patients Who Have Received One Prior Therapy.NEWS2: Pharma Stock Roundup: MRK Impresses at ASCO, LLY Gets FDA Nod for Olumiant.
2018-06-11: NEWS1: JAK Inhibitors' Prospects Strong: 4 Stocks Ruling the Space.NEWS2: JAK Inhibitors' Prospects Strong: 4 Stocks Ruling the Space.NEWS3: Abbvie/Roche's Leukemia Drugs Combination Gets FDA Approval.NEWS4: Abbvie/Roche's Leukemia Drugs Combination Gets FDA Approval.NEWS5: The Zacks Analyst Blog Highlights: Bristol Myers, Merck, Roche, Lilly and AbbVie.NEWS6: The Zacks Analyst Blog Highlights: Bristol Myers, Merck, Roche, Lilly and AbbVie.NEWS7: Abbvie/Roche&apos;s Leukemia Drugs Combination Gets FDA Approval.NEWS8: JAK Inhibitors&apos; Prospects Strong: 4 Stocks Ruling the Space.NEWS9: The Zacks Analyst Blog Highlights: Bristol Myers, Merck, Roche, Lilly and AbbVie.
2018-06-12: NEWS1: AbbVie Presents Additional Outcomes Data from Three Upadacitinib Phase 3 Studies in Rheumatoid Arthritis at the Annual European Congress of Rheumatology (EULAR 2018).

Answer: Decrease